| CONTEXT: Commercial announcement of an RWE market analysis report. Unsurprisingly buoyant predictions of double digit growth forecasts across the board. IMPACT: low READ TIME: 5 mins Quality Level Mean [1 – 10]: 6 1. “In modern healthcare, the applications of real world data-based insights are vast, ranging from drug discovery to supporting regulatory decision-making; in fact, the US FDA routinely uses real world evidence to monitor post market safety of drugsRoots Analysis has announced the addition of “Pharmaceutical and Life Sciences Real World Evidence Market, (2nd Edition), 2021-2030” report to its list of offerings.The digitization of data and advances in information processing, have led to the development of a wide array of tools and analytical algorithms that can now be used to mine pharmaceutical big data.” 2. “Presently, big pharmaceutical companies are estimated to spend nearly USD 20 million on an annual basis, on the generation of real world evidence to support their respective product development programs.To order this 350+ page report, which features 140+ figures and 170+ tables, please visitKey Market InsightsOver 240 companies claim to offer real world evidence-related services for various applicationsMore than 45% of these companies are start-ups / small sized players (with less than 50 employees).” 3. “It is also worth highlighting that 27% of the stakeholders in this market claim to use patient powered data; the second most popular source of real world data that is used by 26% of service providers is clinical setting data.More than 90% of the companies involved in this upcoming field of research, are based in the developed regionsWithin North America, most of the real world evidence focused companies are headquartered in the US.” 4. “Amidst the COVID-19 pandemic, several trials focused on the novel coronavirus related condition have been informed using real world data.North America and Europe are anticipated to capture over 65% of the market share by 2030Based on the analysis in the report, the North American real world evidence market is estimated to grow at the fastest pace (around 16% annualized growth), in terms of service revenues.” 5. “To request a sample copy / brochure of this report, please visitKey Questions AnsweredWho are the leading players offering real world evidence-related services?What is the current regulatory framework related to generation of real world data across various geographies?What are the key drivers of acquisition activity within the real world evidence market?Where in the world are clinical trial informed using real world evidence, being conducted?How has the COVID-19 pandemic impacted the real world evidence market?What is the cost saving potential associated with the use of real world evidence in drug discovery research?How is the current and future opportunity likely to be distributed across key market segments?The USD 4.5 billion (by 2030) financial opportunity within the real world evidence market has been analyzed across the following segments:Type of ApplicationEarly Stage ResearchClinical DevelopmentRegulatory Approval, Pricing / ReimbursementPost-Approval StudiesTypes of Real World Data SourcesMedical ClaimsClinical TrialsClinical SettingPatient PoweredOther Data SourcesTherapeutic AreaAutoimmune DisordersCardiovascular DisordersInfectious DiseasesMetabolic DisordersNeurological / Psychiatric DisordersOncological DisordersRespiratory DisordersOther DisordersGeographyNorth AmericaEuropeAsia-PacificLatin AmericaMiddle East and North AfricaRest of the WorldThe report features inputs from eminent industry stakeholders, according to whom the use of real world evidence has the potential to reduce drug approval timelines by about five years, and the associated capital investment in R&D, by 50-60%.” Source URL: https://www.openpr.com/news/2251205/the-real-world-evidence-rwe-market-is-projected-to-be-worth-usd |